Ivabradin Heumann (Ivabradine Oxalate)

Ivabradine selectively blocks the funny (If) current in the sinoatrial node, the heart’s natural pacemaker. By inhibiting this current, the drug slows the spontaneous depolarisation of pacemaker cells, resulting in a reduced heart rate without affecting contractility or blood pressure.

The specific dose of Ivabradin Heumann is determined by the prescribing clinician based on the patient’s clinical condition, heart rate, and response to therapy. Dosage adjustments are made according to individual therapeutic goals and tolerability.

The safety of ivabradine in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by selectively inhibiting the If current without affecting myocardial contractility or blood pressure. Beta‑blockers act on beta‑adrenergic receptors and also reduce contractility and blood pressure, which may be advantageous or limiting depending on the patient’s overall cardiovascular profile.

Ivabradin Heumann should be stored at temperatures below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency.

Ivabradin Heumann is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed. Administration timing and frequency are set by the prescribing clinician according to the patient’s therapeutic needs.

The most serious risks include severe bradycardia, atrial fibrillation, symptomatic hypotension, heart block, and rare visual disturbances that may lead to vision loss. Patients should be monitored for these events, especially during dose initiation and when combined with other heart‑rate‑lowering agents.

Ivabradin Heumann is contraindicated in patients with severe hepatic impairment, sick sinus syndrome, or those with a resting heart rate below 50 beats per minute. It should also be avoided in individuals taking strong CYP3A4 inhibitors unless the prescriber decides otherwise.